- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01542918
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale for the Proposed Study
There is evidence that immunomodulatory drugs such as lenalidomide stimulate immune effectors such as natural killer (NK) cells, and thus promote rituximab efficacy via ADCC. Because of the evidence for synergy between rituximab and lenalidomide in NHL, patients who do not respond to lenalidomide monotherapy will receive combined intravenous plus intraventricular rituximab in addition to lenalidomide. To maximize delivery to the central nervous system (CNS), the investigators propose to administer rituximab via both intravenous and intraventricular routes. The rationale for intraventricular administration of rituximab is the demonstration that approximately 0.1% of systemically administered rituximab penetrates the cerebral spinal fluid (CSF) but that intraventricular administration of rituximab is both feasible and achieves high concentrations that are associated with anti-lymphoma activity. This study will thus build upon the two Phase 1 trials of intraventricular rituximab that have been conducted at University of California, San Francisco (UCSF) to define the safety of the intraventricular route of administration; this study will, however, be the first to evaluate the combination of intraventricular plus intravenous treatment.
The rationale for intravenous administration of rituximab in recurrent CNS lymphoma is that the blood-brain-barrier is likely partially disrupted, particularly when there is lymphoma-associated contrast enhancement detectable on the MRI, and the fact that there is evidence for activity when rituximab is administered intravenously, both as monotherapy (Batchelor et al., 2011) and potentially in combination with chemotherapy.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ability to give written informed consent and willingness to comply with the requirements of the protocol
- Age eighteen years or older
- Tumors must be CD20+ on prior pathologic analysis
- All prospective participants must have an Ommaya reservoir (or equivalent ventricular access device) inserted as part of their standard clinical care prior to initiation of study treatment.
- No concurrent methotrexate, thiotepa, cytarabine, or investigational agents
- Absolute neutrophil count (ANC) > 1,500 (growth factors permitted)
- Platelets >50,000 (platelet transfusion allowed)
- Total bilirubin </= 1.5 x upper limit of normal (ULN)
- aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase (SGOT)) and alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase (SGPT)) </= 3 x ULN.
- Stable dose of glucocorticoids pre-therapy. If patients are receiving dexamethasone, the dose of dexamethasone should not increase during the 96 hours prior to initiation of therapy.
- Renal function assessed by calculated creatinine clearance. Patients must have calculated creatinine clearance (CrCl) >/= 60ml/min by Cockcroft-Gault formula or 24 hour urine demonstrating CrCl >/= 60ml/min .
- Females of childbearing potential (FCBPs)† must have a negative serum or urine pregnancy test with a sensitivity of at least 25 Milli-International Units per millilitre (mIU/mL) within 10 - 14 days and again within 24 hours prior to receiving lenalidomide for Cycle 1 and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBPs must also agree to ongoing pregnancy testing and for 28 days after receiving their last dose of lenalidomide.
- Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy.
- Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to aspirin may use warfarin or low molecular weight heparin).
- All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.
Exclusion Criteria:
- Intraventricular chemotherapy or radiation therapy within 4 days of starting treatment
- Intravenous rituximab within 30 days of starting treatment
- Persistent neurotoxicity from intraventricular methotrexate, cytarabine, thiotepa
- Anticipated survival of less than 1 month
- Pregnant women and women of child-bearing potential who are not using an effective method of birth control.
- Known hypersensitivity to thalidomide or lenalidomide
- The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
- Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.
- Contraindication to aspirin. If unable to take aspirin, contraindication to warfarin or low molecular weight heparin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study intervention
Lenalidomide Plus Rituximab
|
Formulation of Dosage forms: 5 mg, 10 mg, 15 mg and 25 mg capsules. Dosage: 10 mg - 30 mg (Treatment 1 and Treatment 2) Route of administration: Oral
Other Names:
Formulation of Dosage forms: 100 mg/IO mL and 500 mg/50 mL solution in a single-use vial Dosage: 375 mg/m2, intravenous (Treatment 2, Cycle 1 only); 25 mg intraventricular injection (Treatment 2, all cycles) Route of administration: Intravenous (Treatment 2, Cycle 1 only); Intraventricular injection (Treatment 2, all cycles)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To establish the maximal tolerated dose (MTD) of Lenalidomide in patients with recurrent CNS NHL and intraocular NHL
Time Frame: Participants will be followed for the duration of treatment, an expected average of 4 months.
|
Participants will be followed for the duration of treatment, an expected average of 4 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To define the extent of cerebrospinal fluid (CSF) penetration of lenalidomide.
Time Frame: Participants will have CSF withdrawn every 4 weeks while on treatment. Average study participation is approximately 4 months.
|
Participants will have CSF withdrawn every 4 weeks while on treatment. Average study participation is approximately 4 months.
|
|
To assess the clinical efficacy Lenalidomide monotherapy as measured by cytologic, neurologic, radiographic, and ocular (for patients with intraocular lymphoma) response criteria.
Time Frame: Participants will have weekly evaluations at clinic visits for the duration of treatment. Average study participation is approximately 4 months.
|
Participants will have weekly evaluations at clinic visits for the duration of treatment. Average study participation is approximately 4 months.
|
|
To define the immunological effects of lenalidomide using flow-cytometry CSF as well as genomic markers of recurrent/refractory CNS lymphoma.
Time Frame: Participants will have CSF withdrawn every 4 weeks while on treatment. Average study participation is approximately 4 months.
|
Participants will have CSF withdrawn every 4 weeks while on treatment. Average study participation is approximately 4 months.
|
|
To assess the clinical efficacy of combined intraventricular plus systemic rituximab administration in combination with lenalidomide as measured by cytologic, neurologic, and radiographic response criteria.
Time Frame: Participants will have weekly evaluations at clinic visits for the duration of treatment. Average study participation is approximately 4 months.
|
Objective only applies to patients with recurrent CNS lymphoma not responding to lenalidomide as monotherapy
|
Participants will have weekly evaluations at clinic visits for the duration of treatment. Average study participation is approximately 4 months.
|
To determine a potential impact of intravenous rituximab administration on the rate of rituximab clearance from the CSF after intraventricular rituximab administration.
Time Frame: Participants will have CSF withdrawn every 4 weeks while on treatment. Average study participation is approximately 4 months.
|
Participants will have CSF withdrawn every 4 weeks while on treatment. Average study participation is approximately 4 months.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: James Rubenstein, MD, PhD, University of California, San Francisco
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Neoplasms by Site
- Disease Attributes
- Eye Neoplasms
- Lymphoma
- Recurrence
- Intraocular Lymphoma
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Lenalidomide
- Rituximab
Other Study ID Numbers
- 112530
- NCI-2013-00056 (Registry Identifier: Cancer Trial Reporting Program)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intraocular Lymphoma
-
Peking Union Medical College HospitalRecruitingPrimary Intraocular LymphomaChina
-
The Lymphoma Academic Research OrganisationCompletedIntraocular Lymphoma | Primary Central Nervous LymphomaFrance
-
University of California, San FranciscoCompletedIntraocular Lymphoma | Central Nervous System LymphomaUnited States
-
Peking Union Medical College HospitalBeijing Tongren Hospital; Southern Medical UniversityRecruitingPrimary Vitreoretinal LymphomaChina
-
Peking Union Medical College HospitalRecruiting
-
Vinodh Kakkassery, MDUniversity Hospital Tuebingen; University Hospital Schleswig-HolsteinNot yet recruiting
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Adult Diffuse Large Cell Lymphoma | Intraocular Lymphoma | Central Nervous System Lymphoma | B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma | Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System and other conditionsUnited States
-
National Taiwan University HospitalNot yet recruitingPrimary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
-
Sun Yat-sen UniversityEnrolling by invitation
-
Nidek Co. LTD.Not yet recruitingIntraocular PressureUnited Kingdom
Clinical Trials on Lenalidomide
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedMyelodysplastic SyndromeUnited States
-
Grupo Español de Linfomas y Transplante Autólogo...Celgene Corporation; Dynamic Science S.L.; Thermo Fisher Scientific, IncCompleted
-
Celgene CorporationICON Clinical ResearchCompletedMyelodysplastic SyndromesGermany, Israel, United Kingdom, Spain, Belgium, Italy, France, Netherlands, Sweden
-
Boston VA Research Institute, Inc.Celgene Corporation; Edward Hines Jr. VA Hospital; Michael E. DeBakey VA Medical... and other collaboratorsCompletedMultiple MyelomaUnited States
-
Swiss Group for Clinical Cancer ResearchTerminatedLymphomaSwitzerland, Norway, Sweden
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital and other collaboratorsTerminatedWaldenstrom's MacroglobulinemiaUnited States
-
University Hospital, ToulouseCelgene Corporation; Janssen-Cilag Ltd.Completed
-
CelgeneCompletedRelapsed or Refractory Chronic Lymphocytic LeukemiaUnited States, Canada, United Kingdom, France, Germany, Spain, Italy, Sweden
-
Groupe Francophone des MyelodysplasiesUnknownMyelodysplastic SyndromesFrance